Canine mammary mixed tumours: Immunohistochemical expressions of EGFR and HER-2

Australian Veterinary Journal

Volumn 89, Issue 8, 2011, Pages 312-317

  Bertagnolli, A C ^a   Ferreira, E ^b   Dias, E J ^b   Cassali, G D ^b  

^a University of Rio Doce Valley   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Dogs; Immunohistochemistry; Mammary gland; Neoplasm; Oncogene

Indexed keywords

CANIS FAMILIARIS;

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN;

ANIMAL; BREAST NEOPLASMS; DOG; DOG DISEASES; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; MIXED TUMOR; PATHOLOGY; VETERINARY;

ANIMALS; BREAST NEOPLASMS; DOG DISEASES; DOGS; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIXED TUMOR, MALIGNANT; RECEPTOR, ERBB-2;

EID: 79960717578     PISSN: 00050423     EISSN: 17510813     Source Type: Journal    
DOI: 10.1111/j.1751-0813.2011.00803.x     Document Type: Article

References (45)

1. Misdorp W, Else W, Hellmén E, Lipscomb TP. Histological classification of the mammary tumors of the dog and the cat. In: World Health Organization international histological classification of tumors of domestic animals. Armed Forces Institute of Pathology, American Registry of Pathology, Washington, DC, 1999;18-24.
2. Seifert G. Histological typing of salivary gland tumours In: World Health Organization international histological classification of tumours. Springer-Verlag, Berlin, 2005;122-129.
3. Li Volsi VA, Perzin KH. Malignant mixed tumors arising in salivary glands. 1. Carcinomas arising in benign mixed tumors: a clinicopathologic study. Cancer 1977;39:2209-2230.
4. Downward J, Yarden Y, Mayes EN etal. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 1984;307:521-527.
5. Bargman CI, Hung MC, Weinberg RA. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 1986;319:226-230.
6. Bacus SS, Zelnick CR, Plowman G, Yarden Y. Expression of the erbB-2 family of growth factor receptors and their ligands in breast cancers: Implication for tumor biology and clinical behavior. Am J Clin Pathol 1994;102:13-24.
7. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001;7:2958-2970.
8. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000;19:6550-6565.
9. Riedel F, Götte K, Li M, Grandis JR. EGFR antisense treatment of human HNSCC cell lines down-regulated VEGF expression and endothelial cell migration. Int J Oncol 2002;21:11-16.
10. Slamon DJ, Clark GM, Wong SG etal. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182.
11. Lodato RF, Maquire JR HC, Greene MI, Weiner DB, Li Volsi VA. Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast. Mod Pathol 1990;3:449-454.
12. Shmitt FC, Figueiredo P, Lacerda M. Expression of c-erbB-2 protein and DNA ploidy in breast carcinogenesis. Arch Pathol Lab Med 1995;119:815-820.
13. Xu R, Perle MA, Inghirami G etal. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material. Mod Pathol 2002;15:116-124.
14. Vogel CL, Cobleigh MA, Tripathy D etal. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-726.
15. Konecny G, Giovanni P, Pegram M etal. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor positive primary breast cancer. J Natl Cancer Inst 2003; 95:142-153.
16. Klijn JGM, Look MP, Portengen H, Alexieva-Figusch J, Van Putten WLJ. The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: Results of a 10 year follow-up study. Breast Cancer Res Treat 1994;29:73-83.
17. Bhargava R, Gerald WL, Li AR, Quilu P, Priti L, Ladanyi M. EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod Pathol 2005;18:1027-1033.
18. Tsutsui S, Ohno S, Murakami S, Hachitanda Y, Oda S. Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer. Breast Cancer Res Treat 2002;71:67-75.
19. Cho EY, Han JJ, Choi YL, Kim K, Lyun Y. Comparison of her-2, EGFR and cyclin d1 in primary breast cancer and paired metastatic lymph nodes: An immunohistochemical and chromogenic in situ hybridization study. J Korean Med Sci 2008;23:1053-1061.
20. Gori S, Sidoni A, Colozza M etal. EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab. Ann Oncol 2009;20:648-654.
21. Leibl S, Moinfar F. Metaplastic breast carcinomas are negative for Her-2 but frequently express EGFR (Her-1): potential relevance to adjuvant treatment with EGFR tyrosine kinase inhibitors? J Clin Pathol 2005;58:700-704.
22. Viale G, Rotmensz N, Maisonneuve P etal. Invasive ductal carcinoma of the breast with the triple-negative phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Res Treat 2009;116:317-328.
23. Di Palma S, Skalova A, Vanieek TS etal. Non-invasive (intracapsular) carcinoma ex pleomorphic adenoma: recognition of focal carcinoma by HER-2/neu and MIB1 immunohistochemistry. Histopathology 2005;46:144-152.
24. Matsubayashi S, Yoshihara T. Carcinoma ex pleomorphic adenoma of the salivary gland: an immunohistochemical study. Eur Arch Otorhinolaryngol 2007;264:789-795.
25. Martín de Las Mulas J, Ordás J, Millán Y, Fernández-Soria V, Cajal SR. Oncogene HER-2 in canine mammary gland carcinomas: an immunohistochemical and chromogenic in situ hybridization study. Breast Cancer Res Treat 2003;80:363-367.
26. Dutra AP, Granja NVM, Schmitt F, Cassali GD. cerbB-2 expression and nuclear pleomorphism in canine mammary tumors. Braz J Med Biol Res 2004;37: 673-681.
27. Rungsipipat A, Tateyama S, Yamaguchi R etal. Immunohistochemical analysis of c-yes and cerbB-2 oncogene products and p53 tumor suppressor protein in canine mammary tumors. J Vet Med Sci 1999;6:27-32.
28. Ahern TE, Bird RC, Bird AE, Wolfe LG. Expression of the oncogene c-erbB-2 in canine mammary cancers and tumor-derived cell lines. Am J Vet Res 1996;57:693-696.
29. Hsu WL, Huang WM, Liao JW, Wong L, Chang S. Increased survival in dogs with malignant mammary tumors overexpressing HER-2 protein and detection of a silent single nucleotide polymorphism in the canine HER-2 gene. Vet J 2009;180:116-123.
30. Gama A, Alves A, Schmitt F. Identification of molecular phenotypes in canine mammary carcinomas with clinical implications: application of the human classification. Virch Arch 2008;453:123-132.
31. Nerurkar VR, Seshadri R, Mulherkar R etal. Receptors for epidermal growth factor and estradiol in canine mammary tumors. Int J Cancer 1987;40:230-232.
32. Rutteman GR, Foekens JA, Portengen H etal. Expression of epidermal growth factor receptor (EGFR) in non-affected and tumorous mammary tissue of female dogs. Breast Cancer Res Treat 1994;30:139-146.
33. Donnay I, Devleeschouwer N, Wouters-Ballman P, Leclercq G, Verstegen J. Relationship between receptors for epidermal growth factor and steroid hormones in normal, dysplastic and neoplastic canine mammary tissues. Res Vet Sci 1996;60:251-254.
34. Gama A, Gärtner F, Alves A, Schmitt F. Immunohistochemical expression of epidermal growth factor receptor (EGFR) in canine mammary tissues. Res Vet Sci 2009;87:432-437.
35. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer: experience from a large study with long-term followup. Histopathology 1991;19:403-410.
36. Wolff AC, Hammond MEH, Schwartz JN etal. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-145.
37. Moulton JE, Taylor D, Dorn CR, Andersen AC. Canine mammary tumors. Vet Pathol 1970;7:289-320.
38. Genelhu MCLS, Cardoso SV, Gobbi H, Cassali GD. A comparative study between mixed-type tumors from human salivary and canine mammary glands. BMC Cancer 2007;7:218.
39. Bertagnolli AC, Cassali GD, Genelhu MCLS etal. Immunohistochemical expression of p63 and Δnp63 in mixed tumors of canine mammary glands and its relation with p53 expression. Vet Pathol 2009;46:407-415.
40. Pavelic K, Banjac Z, Pavelic J, Spaventi S. Evidence for a role of EGF receptor in the progression of human lung carcinoma. Anticancer Res 1993;13:1133-1138.
41. Skálova A, Starek I, Vanecek T etal. Expression of Her-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in situ hybridisation and immunohistochemistry. Histopathology 2003;42:348-356.
42. Freitas LLL. Biomarker analysis in carcinoma ex pleomorphic adenoma at an early phase of carcinomatous transformation. Int J Surg Pathol 2005;13:337-342.
43. Ettl T, Schwarz S, Kleinsasser N etal. Overexpression of EGFR and absence of C-KIT expression correlate with poor prognosis in salivary gland carcinomas. Histopathology 2008;53:567-577.
44. Muller S, Vigneswaran N, Gansler T etal. C-erbB-2 oncoprotein expression and amplification in pleomorphic adenoma and carcinoma ex pleomorphic adenoma: relationship to prognosis. Mod Pathol 1994;7:628-632.
45. Reis Filho JS, Milanezi F, Carvalho S etal. Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis. Breast Cancer Res 2005;7:1028-1035.